Gen-Probe at outperform by BRC

RBC Capital Markets analyst William R. Quirk rated Gen-Probe Inc. at outperform, average risk, due to the company's many opportunities in several different testing segments. The company appears to be a leader in the sexually transmitted disease market, with an 80% market share, according to the analyst's survey. RBC increased its second-quarter clinical diagnostics revenue estimate to $41.2 million from $39.2 million. Fiscal-year 2006 revenue and earnings-per-share estimates were also increased to $346.6 million from $343.0 million, and $1.38 from $1.37, respectively. Revenue and earnings-per-share estimates for 2007 were unchanged. Shares of the San Diego-based medical device company were down 92 cents, or 1.76%, at $51.41 on volume of 393,329 shares versus the three-month running average of 381,756 shares. (Nasdaq: GPRO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.